Dublin, March 20, 2019 (GLOBE NEWSWIRE) -- The "Global Spinal Muscular Atrophy Market (By Drugs - Spinraza, Branaplam & Reldesemtiv; By Region - North America & Europe) Market Outlook 2025" report has been added to ResearchAndMarkets.com's offering.

Expected approval of gene therapy for treatment of spinal muscular atrophy is set to emerge as the game-changer in global spinal muscular atrophy therapeutics market. FDA approval of Zolgensma, experimental gene therapy by Novartis is awaited in the first half of the year 2019. It would provide a cost-effective alternative to expensive Spinraza therapy.

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the part of central nervous system which controls voluntary muscle movements. It is progressive hereditary neuromuscular disorder with various degrees of severity resulting in respiratory and mobility impairment. It is caused due to loss of specialized nerve cells, called motor neurons, in the spinal cord and brainstem. SMA can be categorized into four sub-types on the basis of severity - Type I or Infantile, Type II or Intermediate, Type III or Juvenile and Type IV or Adult. SMA type 1 is the most severe form with highest mortality rate.

SMA patients had no treatment option previously prior to approval of the drug SPINRAZA which is the first and only therapy approved to treat SMA. There are several therapy in clinical trial phase which is expected to get approval soon. Growth of global spinal muscular atrophy market is propelled by the prevalence of spinal muscular atrophy, government impetus, growing consumer awareness and increasing funding for R&D. However, the market faces several challenges due to the high cost of treatment and lower market penetration of drug therapy for the treatment of SMA.

Global Spinal Muscular Atrophy Market Outlook 2025 provides in-depth analysis of the current scenario, detailed market outlook of the global spinal muscular atrophy market with coverage on major therapeutics such as Spinraza, Branaplam & Reldesemtiv. Future forecasts of spinal muscular atrophy market overall and across various sub-segments till 2025 is provided in the report. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the global spinal muscular atrophy market include Biogen Inc., Cytokinetics Inc., AveXis Inc., F. Hoffman -La Roche & Ionis Pharmaceuticals Inc., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in the global spinal muscular atrophy market.

Market Segments

• Spinraza
• Branaplam
• Reldesemtiv

Key Vendors

• Biogen Inc.
• Cytokinetics Inc.
• AveXis Inc.
• F. Hoffman -La Roche
• Ionis Pharmaceuticals Inc.

Key Topics Covered:

1. Executive Summary

2. Research Methodology

3. Spinal Muscular Atrophy
3.1 Overview
3.1.1 Types of Diseases
3.1.2 Symptoms of SMA
3.1.3 Diagnosis of SMA
3.2 Therapy for SMA

4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.1.1 Market Sizing by Value (Actual & Forecasted)
4.1.2 Market Sizing by Volume (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Disease Type
4.2.2 Market Share by Route of Administration
4.2.3 Market Share by Region
4.2.4 Market Share by Patient Age-Group

5. Market Segmentation by Drugs
5.1 Spinraza
5.2 Branaplam
5.3 Reldesemtiv

6. Regional Analysis

7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Gene Therapy for Treatment of Spinal Muscular Atrophy
7.1.2 MRI for SMA Detection
7.1.3 Strategic Collaboration to Develop Novel Small Molecule RNA Splicing Modifiers
7.2 Growth Drivers
7.2.1 Rising Incidences of Spinal Muscular Atrophy (SMA)
7.2.2 Government Impetus
7.2.3 Growing Consumer Awareness
7.2.5 Increasing Funding for R&D
7.3 Challenges
7.3.1 High Cost of Therapy
7.3.2 Low Market Penetration of Drug Therapy

8. Competitive Landscape

9. Company Profiles
9.1 Biogen Inc.
9.2 Cytokinetics, Inc.
9.3 AveXis, Inc.(Novartis AG)
9.4 F. Hoffmann-La Roche AG
9.5 Ionis Pharmaceuticals, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/q5vvvb/global_spinal?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs , Musculoskeletal Disorders Drugs